ArticleCureus2024
Contribution of Anemia to Multidimensional Indices for Predicting Mortality in Hospitalized Patients With Chronic Obstructive Pulmonary Disease (COPD).
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mortality Prediction in Hospitalized COPD Patients Based on FEVJournal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSevere exacerbations are a significant predictor of poor prognosis and mortality in patients with chronic obstructive pulmonary disease (COPD). Multidimensional indices, such as the BODE (BMI, airflow obstruction, dyspnea, and exercise capacity) and ADO indices (age, dyspnea severity, and airflow obstruction), outperform single-variable assessments in predicting survival. However, anemia, a strong predictor of mortality in both the general population and COPD patients, has not been included in the prediction indices. This study aimed to evaluate whether including anemia as a variable enhances the predictive accuracy of these indices for both short-term and long-term mortality in COPD patients.
methodsData from patients who were consecutively admitted for acute exacerbation of COPD were recorded with a minimum follow-up of three years. Patients were divided into two groups: anemic (Hb <12 g/dL in women and Hb <13 g/dL in men) or non-anemic. Modified versions of the BODEx (BMI, airflow obstruction, dyspnea, and exacerbation) and ADO indices that included anemia, termed BODEx-A3 and ADO-A3, were created by adding three points to the original values.
resultsA total of 141 patients were included. Twenty-one (15%) died during the first year after admission, and 48 (34%) died during the three-year follow-up period. The area under the receiver operating characteristic curve (AUC) for predicting one-year mortality was slightly higher with the BODEx-A3 compared to the BODEx (0.83 vs. 0.78) and with the ADO-A3 compared to the ADO (0.81 vs. 0.78). For three-year mortality, the predictive power of the BODEx-A3 (AUC 0.77 vs. 0.67 for BODEx, p<0.001) and ADO-A3 indices (AUC 0.82 vs. 0.77 for ADO, p=0.038) was significantly greater compared to their original versions.
conclusionWe have defined novel multidimensional indices (BODEx-A3 and ADO-A3) for predicting short- and long-term mortality in patients hospitalized with COPD exacerbation. These indices were derived by adding three points to the standard BODEx and ADO scores in anemic patients. Our findings demonstrate that incorporating anemia into the best existing COPD mortality predictor indices significantly improves their predictive capacity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.